Analysts Set Expectations for Charles River Laboratories International, Inc.’s Q4 2024 Earnings (NYSE:CRL)

Charles River Laboratories International, Inc. (NYSE:CRL) – Research analysts at Zacks Research upped their Q4 2024 EPS estimates for shares of Charles River Laboratories International in a research note issued to investors on Monday, April 29th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $3.21 per share for the quarter, up from their previous estimate of $3.20. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $11.01 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q4 2025 earnings at $3.33 EPS.

A number of other analysts also recently weighed in on CRL. Robert W. Baird increased their price target on Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. JPMorgan Chase & Co. lifted their price target on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. UBS Group boosted their price objective on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Finally, Evercore ISI upped their target price on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $253.23.

Charles River Laboratories International Trading Up 1.6 %

CRL opened at $232.69 on Tuesday. Charles River Laboratories International has a twelve month low of $161.65 and a twelve month high of $275.00. The company has a fifty day moving average of $253.02 and a 200-day moving average of $223.58. The stock has a market cap of $11.99 billion, a PE ratio of 25.26, a price-to-earnings-growth ratio of 1.82 and a beta of 1.40. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. Charles River Laboratories International’s revenue for the quarter was down 7.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.98 earnings per share.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently modified their holdings of the company. Czech National Bank raised its position in Charles River Laboratories International by 0.5% in the 1st quarter. Czech National Bank now owns 9,025 shares of the medical research company’s stock worth $2,445,000 after purchasing an additional 41 shares during the period. Cardinal Capital Management raised its position in shares of Charles River Laboratories International by 0.6% in the 4th quarter. Cardinal Capital Management now owns 8,450 shares of the medical research company’s stock worth $1,998,000 after purchasing an additional 47 shares during the last quarter. Massmutual Trust Co. FSB ADV lifted its stake in shares of Charles River Laboratories International by 21.5% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 328 shares of the medical research company’s stock worth $78,000 after buying an additional 58 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its position in Charles River Laboratories International by 5.7% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 1,126 shares of the medical research company’s stock valued at $266,000 after acquiring an additional 61 shares in the last quarter. Finally, Dumont & Blake Investment Advisors LLC lifted its holdings in shares of Charles River Laboratories International by 1.4% during the first quarter. Dumont & Blake Investment Advisors LLC now owns 4,415 shares of the medical research company’s stock valued at $1,196,000 after purchasing an additional 62 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, VP William D. Barbo sold 4,050 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the sale, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the transaction, the vice president now owns 22,879 shares of the company’s stock, valued at $5,685,431.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders have sold a total of 14,932 shares of company stock valued at $3,693,663 over the last quarter. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).